Rachel Riechelmann, MD, PhD, AC Camargo Cancer Canter, São Paulo, Brazil, outlines the rationale behind the GASTHER2 (NCT04168931) study evaluating trastuzumab for patients with advanced gastric cancer with HER2 positive expression in circulating tumour cells. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
